Overview

Combined Modality Treatment of Sarcomas of the Extremities

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
In this study, we aim to define the recommended dose of a VEGFR-TKI (pazopanib) in combination with RT pre-operatively given.
Phase:
Phase 1
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborator:
GlaxoSmithKline